BRIDGEBIO PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.01 USD | -2.91% |
|
+0.25% | -30.62% |
| May. 29 | Transcript : BridgeBio Pharma, Inc. - Special Call | |
| May. 28 | UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating | MT |
Chart calendar BridgeBio Pharma, Inc.
20bfa0a577dc31091dfd9a570f845ce7.f83EzYhYcnwg4F_0tBfw_lyxdNrr-yFNAUuaBHaccYI.FKeglcU9LSsNkSm68y_CsxWcPpmOsE8LQniuYRD0QM4pm7KHwjdLEGmKEg~4538311ebbb2af40b2942cc871846faa
Upcoming events on BridgeBio Pharma, Inc.
Past events on BridgeBio Pharma, Inc.
| 2024-05-29 05:30 pm | International Amyloidosis Symposium |
| 2024-05-29 11:30 am | International Amyloidosis Symposium - Cardiovascular Death or Hospitalization in Transthyretin Amylo |
| 2024-05-29 11:30 am | International Amyloidosis Symposium - TTR is Associated with a Lower Risk of Cardiovascular Hospital |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Acoramidis Improves Clinical Outcomes |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Health Related Quality of Life |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Higher Risk of Mortality |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Rationale & Design |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Acoramidis Significantly Improves NT-proBNP |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Acoramidis May Improve Cardiac Function |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Independent Predictor of Improved Survival in ATTR Cardiomyopa |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - ITT Sensitivity Analysis |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Improved Health Related Quality of Life |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - TTR is Associated with Lower Cardiovascular Mortality |
| 2024-05-15 06:00 pm | Bank of America Merrill Lynch Global Healthcare Conference |
| 2024-05-02 07:30 am | Q1 2024 Earnings Release |
| 2024-04-05 | American College of Cardiology Scientific Meeting |
| 2024-04-03 02:20 pm | Cantor Muscular Dystrophy Symposium |
| 2024-03-05 09:10 am | TD Cowen Healthcare Conference |
| 2024-02-22 07:30 am | Q4 2023 Earnings Release |
| 2024-01-08 11:15 am | JPMorgan Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 40,6 26,7 51.79% | 8,25 22,5 -63.37% | 69,7 78,3 -10.92% | 77,6 80,3 -3.36% | 9,30 11,3 -17.31% | 361 |
|
EBITDA Million USD | Released Forecast Spread | -266 -268 0.65% | -474 -469 -1.06% | -577 -557 -3.53% | -505 -500 -1.16% | -593 -535 -10.93% | -217 |
|
EBIT Million USD | Released Forecast Spread | -266 -272 2.05% | -474 -458 -3.7% | -577 -551 -4.6% | -512 -499 -2.64% | -607 -568 -6.87% | -372 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -289 -293 1.63% | -505 -483 -4.65% | -586 -576 -1.9% | -485 -469 -3.32% | -653 -635 -2.82% | -490 |
|
Net income Million USD | Released Forecast Spread | -261 -271 3.76% | -449 -431 -4.1% | -563 -534 -5.42% | -481 -477 -0.79% | -643 -624 -3.05% | -450 |
|
EPS USD | Released Forecast Spread | -2,48 -2,87 13.63% | -3,80 -3,62 -4.97% | -3,90 -3,74 -4.31% | -3,26 -3,21 -1.52% | -3,95 -3,87 -2.15% | -2,72 |
| Announcement Date | 02/03/20 | 25/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1,69 4,47 -62.13% | 73,7 25,0 195.03% | 0,34 4,67 -92.76% | 1,87 5,03 -62.8% | 1,83 3,23 -43.49% | 1,64 2,99 -45.18% | 4,09 4,49 -8.8% | 1,75 3,79 -53.96% | 211 83,8 152% | 4,48 | 4,48 | 157 | 32,6 | 45,5 |
|
EBITDA Million USD | Released Forecast Spread | -151 -169 10.89% | -71,8 -96,4 25.55% | -124 -146 15% | -129 -116 -11.03% | -125 -132 5.62% | -141 -133 -5.61% | -156 -140 -11.47% | -175 -145 -20.71% | 27,8 -143 119.49% | -141 | -150 | 258 | ||
|
EBIT Million USD | Released Forecast Spread | -151 -163 7.08% | -80,2 -111 27.86% | -124 -139 10.73% | -129 -116 -11.36% | -126 -119 -5.95% | -146 -122 -19.5% | -158 -127 -23.71% | -177 -144 -22.84% | 0,34 -117 100.29% | -187 | -185 | -82,2 | -160 | -155 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -201 -176 -14.37% | -2,56 -80,4 96.82% | -140 -154 8.68% | -141 -125 -12.52% | -143 -132 -8.06% | -161 -134 -19.57% | -179 -142 -26.83% | -170 -165 -3.07% | -36,2 -99,7 63.75% | -209 | -204 | -207 | -178 | -169 |
|
Net income Million USD | Released Forecast Spread | -196 -163 -20.55% | -9,86 -93,7 89.48% | -137 -143 4.08% | -138 -128 -7.62% | -140 -126 -10.86% | -158 -129 -22.65% | -177 -133 -32.9% | -168 -158 -6.25% | -35,2 -122 71.14% | -192 | -192 | -76,9 | -172 | -165 |
|
EPS USD | Released Forecast Spread | -1,35 -1,11 -22.09% | -0,07 -0,67 89.56% | -0,93 -0,99 5.89% | -0,92 -0,85 -8.18% | -0,92 -0,83 -10.92% | -0,98 -0,83 -17.69% | -1,08 -0,81 -32.63% | -0,96 -0,92 -4.25% | -0,20 -0,51 60.72% | -1,06 | -1,05 | -0,31 | -0,89 | -0,81 |
| Announcement Date | 05/05/22 | 04/08/22 | 03/11/22 | 23/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 22/02/24 | 02/05/24 | - | - | - | - | - |
| 2024-07-11 02:00 am | BONESUPPORT HOLDING AB: Q2 2024 Earnings Release |
| 2024-07-15 | SWEDISH ORPHAN BIOVITRUM AB: Q2 2024 Earnings Release |
| 2024-07-22 | BIOGEN INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-23 02:00 am | BIOGAIA AB: Q2 2024 Earnings Release |
| 2024-07-23 | SAMSUNG BIOLOGICS CO.,LTD.: Q2 2024 Earnings Release (Projected) |
| 2024-07-24 | PHARMA MAR, S.A.: Q2 2024 Earnings Release (Projected) |
| 2024-07-24 | GRIFOLS, S.A.: Q2 2024 Earnings Release (Projected) |
| 2024-07-25 01:00 am | UCB: Q2 2024 Earnings Release |
| 2024-07-25 | SK BIOSCIENCE CO.,LTD.: Q2 2024 Earnings Release (Projected) |
| 2024-07-29 | BIOMARIN PHARMACEUTICAL INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for BridgeBio Pharma, Inc.
| 2024-05-23 05:43 am | CONCORD BIOTECH LIMITED: Q4 2024 Earnings Release |
| 2024-05-14 11:35 am | GRIFOLS, S.A.: Q1 2024 Earnings Release |
| 2024-05-12 | ALTEOGEN INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-09 | PHARMARESEARCH CO., LTD.: Q1 2024 Earnings Release |
| 2024-05-09 | MEDY-TOX INC.: Q1 2024 Earnings Release |
| 2024-05-09 04:05 pm | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release |
| 2024-05-09 04:05 pm | ADMA BIOLOGICS, INC.: Q1 2024 Earnings Release |
| 2024-05-09 02:30 am | NXERA PHARMA CO., LTD.: Q1 2024 Earnings Release |
| 2024-05-08 | HUGEL, INC.: Q1 2024 Earnings Release |
| 2024-05-08 04:16 pm | CATALYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- BBIO Stock
- Calendar BridgeBio Pharma, Inc.
